Get the Stockscreener App
1.38
2.22%
0.03
After Hours:
1.39
0.01
+0.72%
In 8 Bio Inc stock is traded at $1.38, with a volume of 97,551.
It is up +2.22% in the last 24 hours and down -26.98% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.35
Open:
$1.44
24h Volume:
97,551
Relative Volume:
1.43
Market Cap:
$13.59M
Revenue:
-
Net Income/Loss:
$-19.44M
P/E Ratio:
-0.5191
EPS:
-2.6585
Net Cash Flow:
$-12.71M
1W Performance:
-3.50%
1M Performance:
-26.98%
6M Performance:
-36.11%
1Y Performance:
-71.11%
1-Day Range:
$1.35
$1.44
1-Week Range:
$1.31
$1.50
52-Week Range:
$1.17
$5.817
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.38 | 13.69M | 0 | -19.44M | -12.71M | -2.6585 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Bio Green Med Solution, Inc. Files Form 8-K with SEC – Company Details, Nasdaq Listing, and Contact Information (April 2026) - Minichart
Boundless Bio, Inc. Files Form 8-K with SEC – Corporate Details, Nasdaq Listing, and Emerging Growth Company Status - Minichart
Boundless Bio (NASDAQ: BOLD) pays $10M to exit long-term lab lease - Stock Titan
Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback - Insider Monkey
Gossamer Bio, Inc. 8-K SEC Filing April 2026 – NASDAQ Listing, Company Details, and Compliance Information - Minichart
Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Gossamer Bio Received Notice of Noncompliance - TradingView — Track All Markets
Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan
Nasdaq warns Gossamer Bio (NASDAQ: GOSS) over sub-$1 share price - Stock Titan
ImmunityBio (NASDAQ: IBRX) Q1 revenue jumps 168% to $44.2M - Stock Titan
Primrose Bio Function Generator™ Combinatorial Genetic Technology Case Study Published in PNAS - Morningstar
8 Most Oversold Penny Stocks to Buy Right Now - Insider Monkey
Adaptin Bio shares approved for OTCQB quotation under ticker APTN; trading to begin in 6-8 weeks - TradingView
Adaptin Bio (APTN) wins OTCQB quotation and advances APTN-101 program - Stock Titan
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan
Entera Bio (NASDAQ: ENTX) completes private placement with BVF funds - Stock Titan
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Instil Bio (TIL) replaces Deloitte with RSM as independent auditor - Stock Titan
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan
GOSS SEC FilingsGossamer Bio 10-K, 10-Q, 8-K Forms - Stock Titan
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
APTN SEC FilingsAdaptin Bio 10-K, 10-Q, 8-K Forms - Stock Titan
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
BIO SEC FilingsBio Rad Labs Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
ImmunityBio (NASDAQ: IBRX) adds $75M non-dilutive cash and converts $25M debt - stocktitan.net
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS
ACET SEC FilingsAdicet Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation - MSN
Vanguard reports zero beneficial holdings in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - stocktitan.net
Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program - Stock Titan
bioAffinity Technologies (BIAF) shares March 2026 investor presentation materials - Stock Titan
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy - Stock Titan
Tevogen Bio Holdings Inc. Files Form 8-K on NASDAQ: Company Details and Key Information for March 2026 - Minichart
Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Tevogen Bio (TVGN) restores Nasdaq bid-price compliance after 1-for-50 reverse split - Stock Titan
bioAffinity Technologies (BIAF) plans CyPath Lung webinar showcasing real-world clinical use - Stock Titan
TELA Sees Growth with FY26 Revenue Projected to Rise at Least 8% - GuruFocus
TELA Bio (NASDAQ: TELA) lifts 2025 sales 16% but posts $38.8M loss - Stock Titan
Medical device maker secures up to $70M after 18% sales gain - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):